DOCSLIB.ORG

Increased Osteopontin in Muscle and Serum from Patients with Idiopathic Inflammatory Myopathies F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Increased Osteopontin in Muscle and Serum from Patients with Idiopathic Inflammatory Myopathies F Increased osteopontin in muscle and serum from patients with idiopathic inflammatory myopathies F. Xiao1, J-Z. Tan1, X. Xu1, B-L. Zhu1, S. Fang2, X-F. Wang1 1Department of Neurology, and 2Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Abstract Objectives Osteopontin (OPN) is a non-traditional pro-inflammatory cytokine and is involved in muscle regeneration and inflammation. The aim of this study was to investigate the expression of OPN in skeletal muscle and serum of patients with IIMs. Methods 45 patients with IIMs (27 with PM and 18 with DM) were included in the study. Patients received initial prednisone therapy (1–1.5 mg/kg/day) without other immunosuppressive agents. Muscle biopsies were taken before start of treatment and serum samples were collected from each patient before and after corticosteroid treatment. The expression of OPN in skeletal muscle was using immunofluorescence staining and western blotting. Serum OPN levels were detected by enzyme-linked immunosorbent assays (ELISA). Results OPN expression was increased in muscle samples from IIM patients compared to control muscle. The serum level of OPN was significantly higher in IIM patients than in controls. Moreover, the serum concentrations in the DM subgroup were significantly higher compared to the PM groups. Serum OPN levels positively correlated with creatinine kinase (CK), C-reactive protein (CRP) in PM and DM patients, respectively. After corticosteroid treatment, serum OPN levels decreased significantly in steroid responders compared to baseline, but no significant decrease was observed in steroid non-responders. Conclusion OPN is increased in patients with DM and PM, both in muscle and serum. OPN may play an important role in the pathogenesis of IIMs. Moreover, serum OPN may be a potential biomarker for this illness, and changes in serum OPN may provide an index of therapeutic efficacy. Key words osteopontin, skeletal muscle, idiopathic inflammatory myopathies, polymyositis, dermatomyositis Clinical and Experimental Rheumatology 2015 Increased OPN in muscle and serum of IIMs / F. Xiao et al. Fei Xiao, MD Introduction DM according to the criteria proposed Jia-ze Tan, BS Immune mechanisms are closely in- by Bohan and Peter (17). Individu- Xin Xu, MS volved in the onset and progression of als with overlapping connective tis- Bin-lin Zhu, MD idiopathic inflammatory myopathies sue disease, mixed connective tissue Sheng Fang , MD Xue-feng Wang, MS (IIMs). Infiltration of inflammatory disease, or malignancy were excluded. cells, muscle fibre degeneration, and None of the patients had received im- Please address correspondence to: Dr Xue-feng Wang, necrosis are the primary pathologi- munomodulatory treatment prior to Department of Neurology, cal phenomena in polymyositis (PM). hospital admission. All patients under- The First Affiliated Hospital Macrophages and T lymphocytes play went routine clinical and laboratory of Chongqing Medical University, an important role in muscle fibre dam- assessments, blood parameters includ- Chongqing Key Laboratory of Neurology, age. Cytokines and chemokines acti- ing creatinine kinase (CK), C reactive st 1 You Yi Road, vate, regulate, and control the migra- protein (CRP), erythrocyte sedimenta- Chongqing 400016, China. tion of these cells. Cytokines also play tion rate (ESR) were obtained. Because E-mail: [email protected] a vital role in IIMs (1), and interactions PM and DM mainly affect the proximal Received on October 29, 2014; accepted in revised form on February 10, 2015. among various cytokines may enhance limbs, in order to facilitate the analysis, inflammatory responses. Interferon γ we examinated, recorded and analysed © Copyright CLINICAL AND (IFN-γ) and tumour necrosis factor α the muscle powers of the biceps bra- EXPERIMENTAL RHEUMATOLOGY 2015. are upregulated in dermatomyositis chii, the deltoids in the upper limbs and (DM), PM, and inclusion body myositis quadriceps femoris in the lower limbs (IBMs) (2). IFN-α and -β are implicat- according to Medical Research Council ed in innate immune responses in DM (MRC) scale. We averaged the mus- (3), and IFN-γ is regarded as an impor- cular strengths of the biceps brachii, tant regulator of IIMs (4, 5). the deltoids and quadriceps femoris in Osteopontin (OPN) is an acidic glyco- the same patient, and regard it as the protein expressed in a wide variety of proximal muscle strength of the patient cells including osteoblasts, macrophag- in the study. Global disease activity of es, lymphocytes, endothelial cells, patient was evaluated by the visual ana- skeletal muscle cells, fibroblasts, and logue scales (VAS) score of the Myosi- tumor cells (6-9). OPN is an important tis Disease Activity Assessment Tool regulator of bone resorption and for- (MDAAT) [18] before treatment. They mation. In recent years, OPN has also received initial prednisone therapy been recognised as a non-traditional (1–1.5 mg/kg/day) without other im- pro-inflammatory cytokine. OPN up- munosuppressive agents. We also used regulates expression of both IFN-γ and MDAAT (18) 2 months after corticos- interleukin 12 (IL-12) (10-12). teroid treatment to assess the efficacy OPN expression is significantly higher of treatment. Patients who showed ob- in muscles of patients with Duchenne vious improvement in muscle strength muscular dystrophy and injury (13-15), (a change of at least one grade based suggesting that it may be involved in on the MRC scale) and MDAAT scores muscle regeneration and inflammation. (decrease in disease activity of ≥10 OPN expression is also elevated in the units) were considered to be responsive dermis of patients with DM (16). How- to corticosteroid treatment (19). ever, the expression of OPN has not For muscle specimen controls, we se- yet been studied in the muscle of IIMs. lected ten patients (four men and six Thus, in this paper, we evaluated the women; aged 14 to 60 years) suspect- expression of OPN in skeletal muscle, ed of having a neuromuscular disease, and the serum concentration of OPN, but having normal results for serum in patients with IIMs. In addition, we CK, muscle histology, histochemistry, compared OPN serum levels before immunohistology, and ultrastructural and after glucocorticoid treatment. morphology. We selected another 45 gender- and age-matched healthy indi- Materials and methods viduals as controls for serum measure- Funding: this work was supported by the National Natural Science Foundation Patients and controls ments. of China (no. 81301110) and the National We studied 45 patients with IIMs who The study was conducted in accord- key Clinical Specialist Construction had been admitted to our hospital be- ance with the Helsinki Declaration and Programmes of China. tween July 2010 and June 2014. They was approved by the Research Ethics Competing interests: none declared. were diagnosed with definite PM or Committee of the First Affiliated Hos- 2 Increased OPN in muscle and serum of IIMs / F. Xiao et al. pital of Chongqing Medical University. GmbH, Mannheim, Germany]). The Statistical analysis All participants provided informed debris was pelleted by centrifugation at All data are expressed as mean ± stand- consent. 4°C (16,000 × g for 10 min), and clear ard deviation or median and interquar- supernatants were transferred to new tile range where appropriate. Compari- Sample collection and storage tubes. Protein concentration was meas- sons of more than two groups were per- All patients and controls underwent ured with a bicinchoninic acid protein formed by one-way analysis of variance a diagnostic musculus biceps brachii assay kit (Dingguo Beijing, China). (ANOVA). Differences between two biopsy. Each sample was divided into Protein samples were boiled for 5 min groups were assessed using the inde- two portions. One portion was frozen in the presence of 5× SDS-PAGE load- pendent-samples t-test. To differentiate in liquid nitrogen-cooled isopentane ing buffer. Equal samples (50 μg pro- steroid responders from non-respond- for cryostat sectioning and stored at tein/lane) were subjected to 12% SDS- ers, statistical comparisons of serum -80°C until use. Cryostat sections were PAGE and then electrotransferred onto OPN levels before and after prednisone cut at 8 μm thick. The other portion polyvinylidene difluoride membranes treatment in each patient were analysed was stored directly in liquid nitrogen (Millipore, Billerica, MA, USA). The using the paired t-test. The correlations for immunoblotting analysis. membranes were blocked for 1 h in between serum OPN levels and clini- Venous blood samples (5 ml) were col- Tris-buffered saline (25 mM Tris, pH cal features or laboratory markers were lected from each patient before and 7.5, 150 mM NaCl, and 0.05% Tween evaluated with Spearman’s correlation after corticosteroid treatment. Blood 20) containing 5% non-fat milk powder test in patients with PM and DM, re- samples from controls were obtained and then incubated for 1 h with rab- spectively. Chi square test was used to only once. Serum samples were al- bit anti-osteopontin (1:1000, Abcam) compare sex ratio of PM and DM. All lowed to stand for 30 min at room tem- or rabbit anti–β-actin (1:5000, Santa p-values were derived from two-sided perature, centrifuged at 3000 × g for Cruz Biotechnology). Membranes tests, and p<0.05 was considered to be 15 min to collect the serum, and then were washed and then incubated for 1 statistically significant. Statistical anal- frozen at -80°C until use. h with horseradish peroxidase–labeled yses were performed using Statistical goat anti-rabbit or anti-mouse antibod- Product and Service Solutions version Immunofluorescence ies (1:5000, Santa Cruz Biotechnology) 17.0 software (SPSS Inc., Chicago, IL, Immunofluorescence was performed on for 1.5 h at 37°C. Images were captured USA). consecutive 8 μm–thick cryostat muscle directly using a Gel FX5 chemilumi- sections. To block nonspecific binding, nescence and fluorescence imaging sys- Results sections were preincubated in 10% goat tem (Vilber, France). Band density was Patient characteristics serum (Zhongshan Golden Bridge) for quantified using Quantity One software Twenty-seven patients were diagnosed 30 min at room temperature.
Load more

Recommended publications
  • Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection Against Classical Swine Fever Virus
    Article Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus Yusmel Sordo-Puga 1, Marisela Suárez-Pedroso 1 , Paula Naranjo-Valdéz 2, Danny Pérez-Pérez 1, Elaine Santana-Rodríguez 1, Talia Sardinas-Gonzalez 1, Mary Karla Mendez-Orta 1, Carlos A. Duarte-Cano 1, Mario Pablo Estrada-Garcia 1 and María Pilar Rodríguez-Moltó 1,* 1 Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba; [email protected] (Y.S.-P.); [email protected] (M.S.-P.); [email protected] (D.P.-P.); [email protected] (E.S.-R.); [email protected] (T.S.-G.); [email protected] (M.K.M.O.); [email protected] (C.A.D.); [email protected] (M.P.E.) 2 Central Laboratory Unit for Animal Health (ULCSA), Havana 11400, Cuba; [email protected] * Correspondence: [email protected]; Tel.: +53-7-2504419 Abstract: Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent Citation: Sordo-Puga, Y.; classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In Suárez-Pedroso, M.; Naranjo-Valdéz, order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® P.; Pérez-Pérez, D.; subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged Santana-Rodríguez, E.; 3 intranasally at five, three, and one day post-vaccination with 2 × 10 LD50 of the highly pathogenic Sardinas-Gonzalez, T.; Mendez-Orta, Cuban “Margarita” strain of the classical swine fever virus.
    [Show full text]
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
    International Journal of Molecular Sciences Review Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications Sandra Maria Barbalho 1,2,3,* , Uri Adrian Prync Flato 1,2 , Ricardo José Tofano 1,2, Ricardo de Alvares Goulart 1, Elen Landgraf Guiguer 1,2,3 , Cláudia Rucco P. Detregiachi 1 , Daniela Vieira Buchaim 1,4, Adriano Cressoni Araújo 1,2 , Rogério Leone Buchaim 1,5, Fábio Tadeu Rodrigues Reina 1, Piero Biteli 1, Daniela O. B. Rodrigues Reina 1 and Marcelo Dib Bechara 2 1 Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marilia (UNIMAR), Avenue Hygino Muzzy Filho, 1001, Marília 17525-902, São Paulo, Brazil; urifl[email protected] (U.A.P.F.); [email protected] (R.J.T.); [email protected] (R.d.A.G.); [email protected] (E.L.G.); [email protected] (C.R.P.D.); [email protected] (D.V.B.); [email protected] (A.C.A.); [email protected] (R.L.B.); [email protected] (F.T.R.R.); [email protected] (P.B.); [email protected] (D.O.B.R.R.) 2 School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17506-000, São Paulo, Brazil; [email protected] 3 Department of Biochemistry and Nutrition, Food Technology School, Marília 17525-902, São Paulo, Brazil 4 Medical School, University Center of Adamantina (UniFAI), Adamantina 17800-000, São Paulo, Brazil 5 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo (FOB–USP), Alameda Doutor Octávio Pinheiro Brisolla, 9-75, Bauru 17012901, São Paulo, Brazil * Correspondence: [email protected]; Tel.: +55-14-99655-3190 Received: 6 May 2020; Accepted: 19 May 2020; Published: 20 May 2020 Abstract: Skeletal muscle is capable of secreting different factors in order to communicate with other tissues.
    [Show full text]
  • Increased Peripheral Blood Inflammatory Cytokine Levels In
    www.nature.com/scientificreports OPEN Increased peripheral blood infammatory cytokine levels in amyotrophic lateral sclerosis: a Received: 3 May 2017 Accepted: 20 July 2017 meta-analysis study Published: xx xx xxxx Yang Hu, Chang Cao, Xiao-Yan Qin, Yun Yu, Jing Yuan, Yu Zhao & Yong Cheng Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with poorly understood etiology. Increasing evidence suggest that infammation may play a critical role in the pathogenesis of ALS. Several studies have demonstrated altered levels of blood cytokines in ALS, but results were inconsistent. Therefore, we did a systematic review of studies comparing blood infammatory cytokines between ALS patients and control subjects, and quantitatively combined the clinical data with a meta- analysis. The systematic review of Pubmed and Web of Science identifed 25 studies encompassing 812 ALS patients and 639 control subjects. Random-efects meta-analysis demonstrated that blood tumor necrosis factor-α (TNF; Hedges’ g = 0.655; p = 0.001), TNF receptor 1 (Hedges’ g = 0.741; p < 0.001), interleukin 6 (IL-6; Hedges’ g = 0.25; p = 0.005), IL-1β (Hedges’ g = 0.296; p = 0.038), IL-8 (Hedges’ g = 0.449; p < 0.001) and vascular endothelial growth factor (Hedges’ g = 0.891; p = 0.003) levels were signifcantly elevated in patients with ALS compared with control subjects. These results substantially enhance our knowledge of the infammatory response in ALS, and peripheral blood infammatory cytokines may be used as diagnostic biomarkers for ALS in the future. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal neurodegenerative disease characterized by the degeneration of motor neurons in brain and spinal cord1.
    [Show full text]
  • Expression of Osteopontin, Interleukin 17 and Interleukin 10 Among Rheumatoid Arthritis Sudanese Patients
    Arch Microbiol Immunology 2020; 4 (4): 131-138 10.26502/ami.93650052 Original Article Expression of Osteopontin, Interleukin 17 and Interleukin 10 among Rheumatoid Arthritis Sudanese Patients Mohamed A Eltahir1, Amar M Ismail2, Elhaj NM Babiker1, Mohammed KA Karrar1, Kawthar A Mohammed S Alih3* 1Department of Clinical Chemistry, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan 2Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, Al-Neelain University, Khartoum, Sudan 3General Department, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan *Corresponding Author: Kawthar A Mohammed S Alih, General Department, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan; E-mail: [email protected] Received: 22 October 2020; Accepted: 03 November 2020; Published: 18 November 2020 Citation: Mohamed A Eltahir, Amar M Ismail, Elhaj NM Babiker, Mohammed KA Karrar, Kawthar A Mohammed S Alih. Expression of Osteopontin, Interleukin 17 and Interleukin 10 among Rheumatoid Arthritis Sudanese Patients. Archives of Microbiology & Immunology 4 (2020): 131-138. Abstract Materials and Methods: A case control hospital Background: Rheumatoid arthritis (RA) is the based study for groups of 88 rheumatoid arthritis most common inflammatory arthritis in the world. patients was included from Outpatient Clinic. The Its exact cause is unknown; proinflammatory and control groups matched in numbers, age and sex anti inflammatory cytokines play key roles in the with case. After inform consent, Serum from Both pathophysiology of disease. patients and controls were examined for OPN, IL- 17 and IL-10. Objectives: This study aimed to measure the level of pro inflammatory cytokines Osteopontin (OPN) Results: The mean age of RA patients was 41.0 and interleukin (IL-17) and anti-inflammatory ±11.7 years.
    [Show full text]
  • Antigen-Specific Induced Foxp3 Regulatory T Cells Are Generated
    Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade Ivana R. Ferrer, Maylene E. Wagener, Minqing Song, Allan D. Kirk, Christian P. Larsen, and Mandy L. Ford1 Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322 Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved November 4, 2011 (received for review April 7, 2011) Blockade of the CD40/CD154 pathway potently attenuates T-cell in vivo accumulation of Treg and deletion of graft-specific ef- responses in models of autoimmunity, inflammation, and trans- fectors after CD40/CD154 blockade has not been investigated. plantation. Indeed, CD40 pathway blockade remains one of the To address these questions, we used an ovalbumin (OVA)- most powerful methods of prolonging graft survival in models of expressing transgenic mouse model (20), which allowed us to di- + + transplantation. But despite this effectiveness, the cellular and rectly track both donor-reactive CD4 and CD8 T-cell responses molecular mechanisms underlying the protective effects of CD40 simultaneously over time. Although previous studies have used pathway blockade are incompletely understood. Furthermore, the transgenic models to assess the degree of T-cell deletion after CD154/CD40 blockade (16, 21), none has systematically inter- relative contributions of deletion, anergy, and regulation have not + been measured in a model in which donor-reactive CD4+ and CD8+ rogated the impact of anti-CD154 on the kinetics of both CD4 and CD8+ T-cell deletion and acquisition of effector function. T-cell responses can be assessed simultaneously. To investigate the fi Our results indicated that although CD40/CD154 blockade alone impact of CD40/CD154 pathway blockade on graft-speci c T-cell delayed donor-reactive CD4+ and CD8+ T-cell expansion and responses, a transgenic mouse model was used in which recipients differentiation, the addition of DST was required for antigen- fi + + containing ovalbumin-speci cCD4 and CD8 TCR transgenic T specific T-cell deletion.
    [Show full text]
  • Interferon Gamma Release Assay (IGRA) Interferon Gamma Release Assay (IGRA) Is a Blood Test That Has Recently Been Introduced As Another Method to Diagnose LTBI
    Section 4: TB Screening These cases also included patients that did not have previous exposure to tuberculin. It is imperative that health care providers should have Epinephrine Hypochloride solution (1:1000) and other appropriate agents available for immediate use in the case of a hypersensitivity reaction. As per NACI, recommendations all patients must be monitored for 15 minutes after inoculation. Interferon Gamma Release Assay (IGRA) Interferon gamma release assay (IGRA) is a blood test that has recently been introduced as another method to diagnose LTBI. Therefore, it can complement the TST in certain situations. In general, IGRAs are more specific than the TST in populations vaccinated with BCG, especially if BCG is given after infancy or multiple times. When a person is exposed to MTB it produces many immune cells, which produce various proteins. Among these proteins are interferon gamma or IFN-y. The interferon gamma release assay (IGRA) is a blood test that measures IFN-y. Therefore, if a person has been exposed and infected with TB, IFN-y can be detected with this test. There are two IGRA tests used in Canada, the T-SPOT.TB test and the QuantiFERON®-TB Gold test. Provincial Laboratory (ProvLab) Alberta uses QuantiFERON®-TB Gold (QFT) test in the NWT. Specimens must be received by the regional laboratory and incubated for 16–24 hours. This limits availability of this test in the NWT. IGRA can only be ordered through the Office of the Chief Public Health Officer and Stanton Regional Hospital Specialists who are involved in TB management and treatment. IGRAs require laboratories with adequate equipment and trained personnel to perform the assays.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • 2010 Hepatitis C Treatment Updates
    2010 Hepatitis C Treatment Updates Summer 2010 Treatment Options Conventional Interferon Alone (Monotherapy) Studies in adults have demonstrated that monotherapy with conventional interferon is effective for adults 10-15% of the time. Although children typically respond better than adults to this treatment (27% for genotype 1 and 71% for genotype 2 and 3), subsequent study has confirmed that using conventional interferon in combination with ribavirin produces better treatment outcomes for both adults and children. Thus, conventional interferon alone is no longer recommended for the majority of children requiring HCV therapy. Conventional Interferon Alpha-2b in Combination with Ribavirin (Rebetron for Children) Rebetron was the first drug to be FDA-approved to treat children with hepatitis C. It’s approved for use in children between the ages of 5 and 16 years. Rebetron is a combination drug that contains both Intron A (an interferon alfa-2b) and Rebetol (which is ribavirin). Rebetron is administered as a weight-based dose of oral Rebetol that is taken twice a day. (Rebetol should never be used alone to treat hepatitis C.) The Intron A portion of the treatment is a subcutaneous injection that is given three times weekly for 24 to 48 weeks. Sometimes, problems with anemia or depression can develop with this treatment. When this occurs, doses should be reduced temporarily or permanently until the problem is reversed. Additionally, if uncontrollable thyroid abnormalities (such has hypothyroidism) occur, treatment should be discontinued. Use of conventional interferon alpha-2b in combination with ribavirin has been shown to improve treatment outcomes in adults when compared to using conventional interferon alone.
    [Show full text]
  • High Sensitivity Immunoassays for Detecting Ifn-Gamma in Cytokine Release Syndrome
    APPLICATION NOTE HIGH SENSITIVITY IMMUNOASSAYS FOR DETECTING IFN-GAMMA IN CYTOKINE RELEASE SYNDROME INTRODUCTION T cell expansion with increased Interferon Gamma (IFN-γ) release. Note that increased IFN-γ is also an early and prominent element of CRS. IFN , along with IL-6, IL-10 and TNF-alpha are the Cytokine Release Syndrome (CRS), also known as the “Cytokine -γ core cytokines involved in CRS (2). IFN activates macrophages Storm”, is a systemic inflammatory response characterized at the -γ which secrete excessive amounts of other cytokines such as cellular level by the rapid release of excessive concentrations IL-6, TNF and IL-10. Lastly, it is important to keep in mind that of cytokines (1,2). Patient symptoms range from mild fever to α IFN is pleiotropic and has both harmful and beneficial effects. hypotension, multiorgan system failure, neurotoxicity and death. -γ Although IFN has a harmful role in CRS, it also been correlated CRS is caused by a variety of events, including viral infection, -γ with antiproliferative, proapoptotic and antitumor activities in the antibody-based immunotherapy and cellular immunotherapy. context of cancer (4). In antibody-based immunotherapies, the incidence of CRS is relatively low, however, onset can occur within days and up to We previously described the new 3rd generation R&D Systems® weeks of infusion in cellular immunotherapy. Evidence suggests IFN-γ Quantikine® ELISA kit. Learn more about that assay here. that the risk and severity of CRS is influenced by the type of Here, we describe the R&D Systems® Human IFN-γ Quantikine® therapy, disease burden and patient characteristics, such as age.
    [Show full text]
  • Role of Mitogen-Activated Kinases in Cd40-Mediated T Cell Activation of Monocyte/ Macrophage and Vascular Smooth Muscle Cell Cytokine/Chemokine Production Denise M
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works August 1999 Role of Mitogen-activated Kinases in Cd40-mediated T Cell Activation of Monocyte/ macrophage and Vascular Smooth Muscle Cell Cytokine/chemokine Production Denise M. Milhorn East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Immunology and Infectious Disease Commons Recommended Citation Milhorn, Denise M., "Role of Mitogen-activated Kinases in Cd40-mediated T Cell Activation of Monocyte/macrophage and Vascular Smooth Muscle Cell Cytokine/chemokine Production" (1999). Electronic Theses and Dissertations. Paper 2950. https://dc.etsu.edu/ etd/2950 This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quaiity of the copy subm itted. Broken or indistinct print, colored or poor quality illustrations arxf photographs, print bleedthrough. sutwtandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete m anuscrit and there are missing pages, these wiH be noted.
    [Show full text]
  • Betaferon Data Sheet
    NEW ZEALAND DATA SHEET 1 PRODUCT NAME BETAFERON® Interferon beta-1b 8 MIU Injection with diluent 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Lyophilisate and solvent for solution for injection. BETAFERON® Recombinant Interferon beta-1b 0.25 mg (8.0 million IU) per mL when reconstituted. 1 mL of the reconstituted solution for injection contains 8 million IU (0.25 mg) of interferon beta-1b. 1 mL solution for injection contains 5.4 mg sodium chloride. Interferon beta-1b is produced in Escherichia coli cells by recombinant DNA technology from a strain of Escherichia coli that bears a genetically engineered plasmid containing a modified human interferon beta gene. BETAFERON contains mannitol. For the full list of Excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM BETAFERON is presented as a sterile lyophilised white to off-white cake or powder and solvent for solution for injection. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications BETAFERON is indicated for: • the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (MRI) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded, • the treatment of ambulatory patients, with relapsing-remitting multiple sclerosis (MS) characterised by at least two attacks of neurological dysfunction over a two year period followed by complete or incomplete recovery. • the reduction of frequency and severity of clinical relapses and for slowing the progression of disease in patients with secondary progressive multiple sclerosis 4.2 Dose and method of administration General Treatment with BETAFERON should be initiated under the supervision of a physician experienced in the treatment of multiple sclerosis.
    [Show full text]